CLDI Financials

Income Statement
MetricQ2 2026Q1 2026Q4 2025Q3 2025Q2 2025
Revenue
0
0
0
0
0
Cost of Revenue
0
0
0
0
0
Gross Profit
0
0
0
0
0
Operating Expenses
4.2M
-0.9%
4.2M
-6.2%
4.5M
-11.5%
5.0M
-10.9%
5.7M
R&D
2.6M
-1.1%
2.6M
+9.7%
2.4M
-0.1%
2.4M
-8.9%
2.6M
SG&A
1.6M
-0.5%
1.6M
-24.1%
2.1M
-21.5%
2.7M
-12.5%
3.1M
Operating Income
-4150000
+0.9%
-4187000
+6.2%
-4466000
+11.5%
-5048000
+10.9%
-5664000
EBITDA
-3712000
+1.3%
-3761000
+7.0%
-4043000
+12.5%
-4621000
+12.1%
-5257000
Net Income
-4160000
-1.3%
-4108000
-1.2%
-4059000
+21.7%
-5181000
+10.1%
-5761000
EPS (Basic)
$-2.94
+57.3%
$-6.88
-4.6%
$-6.58
+81.4%
$-35.36
-11.4%
$-31.75
EPS (Diluted)
$-2.94
+57.3%
$-6.88
-4.6%
$-6.58
+81.4%
$-35.36
-11.4%
$-31.75
Shares (Diluted)
1.4M
+119.8%
644.3K
+4.5%
616.5K
+101.0%
306.7K
+70.4%
180.0K
Calidi Biotherapeutics (CLDI) โ€” Financials